Pure Global
NCT02215928

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

Tumor Genomic Profiling: A Personalized Medicine Approach
Stanford University·ClinicalTrials.gov·geneticRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
mutation analysis
Study type
Observational
Intervention type
genetic
Sponsor & location
Primary sponsor
Stanford University
Location
Stanford, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jul 28, 2014
End date
Dec 01, 2024
Enrollment
100 participants
Primary outcome

Feasibility, measured as the proportion of patients with at least one actionable alteration

Summary

This research trial studies using genomic profiling to recommend anticancer treatment to
 patients with cancer that has spread beyond the original site of the tumor (metastatic
 cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect
 genetic changes or abnormalities. This information can then be used to recommend treatments
 that may be more likely to result in a beneficial response. It is not yet known whether
 genomic profiling will detect abnormalities that can be used to make treatment
 recommendations and whether treatment based on genomic profiling is more effective than
 standard treatment.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02215928
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02215928 through Pure Global AI's free database. This phase not specified trial is sponsored by Stanford University and is currently Recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.